Jérusalem

BrainsWay Announces First Draft Proposal for OCD Coverage by a Regional Medicare Administrative Contractor

Retrieved on: 
Tuesday, June 1, 2021

The BrainsWay team has worked closely with the MACs, and specifically Palmetto, to provide the appropriate published clinical literature for Deep TMS in support of this proposed draft LCD.

Key Points: 
  • The BrainsWay team has worked closely with the MACs, and specifically Palmetto, to provide the appropriate published clinical literature for Deep TMS in support of this proposed draft LCD.
  • We look forward to the formal policy from Palmetto, and anticipate that other MACs, over time, will also issue their draft policies for Deep TMS coverage of OCD.
  • We remain committed to working to secure further coverage policy decisions from additional payors in the coming months.
  • The patient selection criteria identified in Palmettos draft LCD is closely aligned with the Clinical TMS Societys recommended OCD coverage policy.

BrainsWay Announces First of its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™

Retrieved on: 
Monday, May 24, 2021

Centenes new policy specifies that coverage will be exclusive for the treatment of OCD utilizing Deep TMS, which is a form of therapy solely associated with BrainsWays patented H-Coil technology.

Key Points: 
  • Centenes new policy specifies that coverage will be exclusive for the treatment of OCD utilizing Deep TMS, which is a form of therapy solely associated with BrainsWays patented H-Coil technology.
  • BrainsWays H7-Coil is designed to penetrate deeper and more medial to stimulate the structures of the brain associated with OCD.
  • The establishment of this positive Deep TMS coverage policy is the first of its kind for OCD in the broader TMS space.
  • This positive coverage decision reflects the large body of compelling clinical evidence supporting the treatment of OCD with our Deep TMS H7-Coil, further differentiating it from traditional TMS coils.

Muslim World League Welcomes Cease-Fire, Urges Action to Address Palestinian Grievances

Retrieved on: 
Friday, May 21, 2021

b"MAKKAH, Saudi Arabia, May 21, 2021 /PRNewswire/ --The Muslim World League (MWL) welcomes the announcement of an unconditional cease-fire to end the recent hostilities in Gaza, Jerusalem and elsewhere.

Key Points: 
  • b"MAKKAH, Saudi Arabia, May 21, 2021 /PRNewswire/ --The Muslim World League (MWL) welcomes the announcement of an unconditional cease-fire to end the recent hostilities in Gaza, Jerusalem and elsewhere.
  • Too many innocent people died in the recent violence.\nThe League emphasizes the peaceful nature of the true, moderate Islam, and notes that Muslims, Christians and Jews share a common Abrahamic heritage.
  • All of our religions hold as sacred the principles of harmonious and peaceful coexistence.
  • We need all sides to come together to re-establish the foundational principles of peace, coexistence and understanding through dialogue and interaction.

Muslim World League Welcomes Cease-Fire, Urges Action to Address Palestinian Grievances

Retrieved on: 
Friday, May 21, 2021

b"MAKKAH, Saudi Arabia, May 21, 2021 /PRNewswire/ --The Muslim World League (MWL) welcomes the announcement of an unconditional cease-fire to end the recent hostilities in Gaza, Jerusalem and elsewhere.

Key Points: 
  • b"MAKKAH, Saudi Arabia, May 21, 2021 /PRNewswire/ --The Muslim World League (MWL) welcomes the announcement of an unconditional cease-fire to end the recent hostilities in Gaza, Jerusalem and elsewhere.
  • Too many innocent people died in the recent violence.\nThe League emphasizes the peaceful nature of the true, moderate Islam, and notes that Muslims, Christians and Jews share a common Abrahamic heritage.
  • All of our religions hold as sacred the principles of harmonious and peaceful coexistence.
  • We need all sides to come together to re-establish the foundational principles of peace, coexistence and understanding through dialogue and interaction.

Friends Of Zion: Jerusalem Prayer Team Founder Mobilizing Support For Israel

Retrieved on: 
Friday, May 21, 2021

b'JERUSALEM, May 21, 2021 /PRNewswire/ -- Dr. Mike Evans, founder of the Friends of Zion Heritage Center in Jerusalem, the world\'s headquarters of the Jerusalem Prayer Team, arrived in Israel this week.\nOn Tuesday morning, Mike Evans and his team headed to the south of Israel, where they met with police officers and municipality workers who showed them around the city of Ashkelon.

Key Points: 
  • b'JERUSALEM, May 21, 2021 /PRNewswire/ -- Dr. Mike Evans, founder of the Friends of Zion Heritage Center in Jerusalem, the world\'s headquarters of the Jerusalem Prayer Team, arrived in Israel this week.\nOn Tuesday morning, Mike Evans and his team headed to the south of Israel, where they met with police officers and municipality workers who showed them around the city of Ashkelon.
  • Evans plans to raise funds for Chabad, and to encourage all members of the Jerusalem Prayer Team to support their work.\nIn addition to the Friends of Zion Heritage Center, Evans is also the founder of the Jerusalem Prayer Team, a movement with over 77 million followers, all dedicated to Defending Israel\'s brand and combating antisemitism\nJust a few days before he arrived in Israel, Mike Evans\' Facebook page, Jerusalem Prayer Team, was attacked by radical Islamists, who flooded it with anti-Semitic and anti-Israel hate speech.
  • The 750 million Evangelicals whom I lead are Israel\'s secret weapon, 77 million of them are members of the Friends of Zion Museum, who follow and support the museum\'s activities and the Jerusalem Prayer Team Corporation, a 100 hundred million dollar Friends of Zion Campus.
  • Evans served as Jerusalem Advisor to former President Trump and he is also the founder of numerous initiatives supporting Israel, including: the Jerusalem Prayer Team, which has 77 million members, and the Holocaust Memorial Museum Corrie ten Boom in Haarlem, The Netherlands.\n'

BrainsWay Reports First Quarter 2021 Financial Results and Operational Highlights

Retrieved on: 
Thursday, May 20, 2021

\xe2\x80\x9cOur revenues of $6.1 million represented a significant 47% increase over our first quarter of 2020, demonstrating the resiliency of our business and continued emergence from the COVID-19 pandemic.

Key Points: 
  • \xe2\x80\x9cOur revenues of $6.1 million represented a significant 47% increase over our first quarter of 2020, demonstrating the resiliency of our business and continued emergence from the COVID-19 pandemic.
  • We believe these accomplishments position us well to generate long-term shareholder value and to advance in our mission to improve health and transform lives.\xe2\x80\x9d\nTotal revenues for the first quarter of 2021 were $6.1 million, compared to $4.2 million in the first quarter of 2020, an increase of 47%.
  • This is compared to an operating loss of $3.6 million during the same period in the prior year.\nAs of March 31, 2021, the Company had cash and short-term deposits of approximately $58.5 million, compared to $17.2 million at December 31, 2020.
  • The significantly increased cash position reflects the completion of the Company\xe2\x80\x99s public offering, which was closed in March 2021 and generated gross proceeds of $45.2 million.\nBrainsWay\xe2\x80\x99s management will host a conference call today, May 20, 2021, at 8:30 a.m. Eastern Time to discuss these results and answer questions.\nThursday, May 20, at 8:30 AM Eastern Time:\n'

Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates

Retrieved on: 
Thursday, May 20, 2021

Treatment with EB612 resulted in a statistically significant decrease in supplemental calcium usage, maintenance of serum albumin-adjusted calcium, and reduction of serum phosphate.

Key Points: 
  • Treatment with EB612 resulted in a statistically significant decrease in supplemental calcium usage, maintenance of serum albumin-adjusted calcium, and reduction of serum phosphate.
  • Despite the challenges of COVID, I am grateful to the patients, investigators and team\xe2\x80\x99s focus to successfully executing the study.
  • Entera\xe2\x80\x99s operating loss was $2.4 million for the quarter ended March 31, 2021, compared to $2.9 million for the quarter ended March 31, 2020.\nResearch and development expenses were $1.2 million for the quarter ended March 31, 2021, compared to $1.6 million for the quarter ended March 31, 2020.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

BrainsWay to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit

Retrieved on: 
Wednesday, May 19, 2021

The Company will also host one-on-one investor meetings at the conference.\nBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • The Company will also host one-on-one investor meetings at the conference.\nBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

BrainsWay to Report First Quarter 2021 Financial Results on May 20, 2021

Retrieved on: 
Thursday, May 6, 2021

Please access the Company\xe2\x80\x99s website at least 10 minutes ahead of the conference call to register.\nBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • Please access the Company\xe2\x80\x99s website at least 10 minutes ahead of the conference call to register.\nBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

BrainsWay Announces Appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer

Retrieved on: 
Wednesday, May 5, 2021

b'CRESSKILL, N.J. and JERUSALEM, May 05, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (\xe2\x80\x9cBrainsWay\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer effective today.\n\xe2\x80\x9cWe are very pleased to announce that Scott Areglado has joined BrainsWay to become our Senior Vice President and Chief Financial Officer,\xe2\x80\x9d stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay.

Key Points: 
  • b'CRESSKILL, N.J. and JERUSALEM, May 05, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (\xe2\x80\x9cBrainsWay\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer effective today.\n\xe2\x80\x9cWe are very pleased to announce that Scott Areglado has joined BrainsWay to become our Senior Vice President and Chief Financial Officer,\xe2\x80\x9d stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay.
  • I believe we are truly at an inflection point in a growing market and that this is a unique opportunity.
  • I look forward to working with the team at BrainsWay to help drive long-term growth and value for our stakeholders.\xe2\x80\x9d\nMr.
  • Since December 2018, he has been Chief Financial Officer of iCAD, Inc., a publicly traded global medical technologies provider of advanced image analysis, having previously served as its Vice President and Corporate Controller (from 2011 to 2018).